Protocol Ledger

NCT05595499 · Phase II · RECRUITING

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Interventional Phase II clinical trial protocol NCT05595499 sponsored by UCLA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-27 Enrollment: 88 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05595499
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)88 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05595499
Protocol FieldVerified Registry Value
NCT IdentifierNCT05595499
Consolidated Lead SponsorUCLA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment88 participants (ESTIMATED)
Registered Start Date2023-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05595499
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCLA Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI